TrialThe oncologist2019

Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

Aleix Prat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.